opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
Company profile
Ticker
OPK
Exchange
Website
CEO
Phillip Frost
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CYTOCLONAL PHARMACEUTICS INC /DE, EXEGENICS INC, eXegenics Inc
SEC CIK
Corporate docs
Subsidiaries
OPKO Instrumentation, LLC • OPKO Pharmaceuticals, LLC • OPKO Diagnostics, LLC • ModeX Therapeutics, Inc. • OPKO Chile, S.A. • Arama Natural Products Distribuidora, Ltda • Pharmacos Exakta S.A. de C.V. • FineTech Pharmaceutical Ltd • OPKO Health Europe, S.L. • OPKO Biologics, Ltd ...
IRS number
752402409
OPK stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
29 Mar 24
8-K/A
Regulation FD Disclosure
28 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Mar 24
ARS
2023 FY
Annual report to shareholders
7 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
NT 10-K
Notice of late annual filing
1 Mar 24
DEF 14A
Definitive proxy
29 Feb 24
8-K
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
27 Feb 24
PRE 14A
Preliminary proxy
16 Feb 24
8-K
Departure of Directors or Certain Officers
9 Feb 24
Transcripts
OPK
Earnings call transcript
2023 Q4
27 Feb 24
OPK
Earnings call transcript
2023 Q3
6 Nov 23
OPK
Earnings call transcript
2023 Q2
3 Aug 23
OPK
Earnings call transcript
2023 Q1
3 May 23
OPK
Earnings call transcript
2022 Q4
23 Feb 23
OPK
Earnings call transcript
2022 Q3
8 Nov 22
OPK
Earnings call transcript
2022 Q2
4 Aug 22
OPK
Earnings call transcript
2022 Q1
10 May 22
OPK
Earnings call transcript
2021 Q4
25 Feb 22
OPK
Earnings call transcript
2021 Q3
29 Oct 21
Latest ownership filings
4
Alice Lin-Tsing Yu
29 Mar 24
4
JOHN A PAGANELLI
29 Mar 24
4
Prem A Lachman
29 Mar 24
4
RICHARD C PFENNIGER JR
29 Mar 24
4
RICHARD M KRASNO
29 Mar 24
4
ROGER MD MEDEL
29 Mar 24
4
PHILLIP MD ET AL FROST
18 Mar 24
4
PHILLIP MD ET AL FROST
14 Mar 24
4
PHILLIP MD ET AL FROST
13 Mar 24
4
PHILLIP MD ET AL FROST
12 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 138.62 mm | 138.62 mm | 138.62 mm | 138.62 mm | 138.62 mm | 138.62 mm |
Cash burn (monthly) | (no burn) | 3.52 mm | 21.47 mm | 11.94 mm | (no burn) | 1.79 mm |
Cash used (since last report) | n/a | 24.07 mm | 146.87 mm | 81.66 mm | n/a | 12.27 mm |
Cash remaining | n/a | 114.55 mm | -8.25 mm | 56.96 mm | n/a | 126.35 mm |
Runway (months of cash) | n/a | 32.6 | -0.4 | 4.8 | n/a | 70.4 |
Institutional ownership, Q3 2023
60.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 223 |
Opened positions | 29 |
Closed positions | 28 |
Increased positions | 56 |
Reduced positions | 62 |
13F shares | Current |
---|---|
Total value | 260.29 bn |
Total shares | 422.06 mm |
Total puts | 1.12 mm |
Total calls | 1.07 mm |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Phillip MD Frost Et Al | 213.89 mm | $267.37 mm |
Vanguard | 39.32 mm | $62.92 bn |
BLK Blackrock | 34.76 mm | $55.61 bn |
Gary J. Nabel | 19.86 mm | $48.45 mm |
Zerhouni Elias A. | 19.78 mm | $48.26 mm |
STT State Street | 9.34 mm | $14.94 bn |
Geode Capital Management | 9.13 mm | $14.61 bn |
D. E. Shaw & Co. | 6.16 mm | $9.86 bn |
Charles Schwab Investment Management | 5.55 mm | $8.88 bn |
IVZ Invesco | 5.16 mm | $8.26 bn |
News
HC Wainwright & Co. Reiterates Buy on OPKO Health, Maintains $3 Price Target
3 Apr 24
Critical Insights From OPKO Health Analyst Ratings: What You Need To Know
1 Apr 24
Barrington Research Maintains Outperform on OPKO Health, Maintains $1.5 Price Target
1 Apr 24
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
28 Mar 24
Labcorp Expands Diagnostic Reach With Strategic Deal For Select Assets Of BioReference Health
28 Mar 24
Press releases
Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. Amidst Groundbreaking Cancer Therapy Innovations
1 Apr 24
Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
28 Mar 24
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
5 Mar 24
NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st
28 Feb 24
Thinking about buying stock in Intuitive Machines, OPKO Health, Ardelyx, AXT Inc, or Clearmind Medicine?
23 Feb 24